Skip to content
Tpoxx, Tecovirimat siga(tecovirimat)
Tpoxx (tecovirimat) is a small molecule pharmaceutical. Tecovirimat was first approved as Tpoxx on 2018-07-13. It is used to treat smallpox in the USA. It has been approved in Europe to treat cowpox, monkeypox, poxviridae infections, smallpox, and vaccinia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
animal diseasesD000820
Trade Name
FDA
EMA
Tpoxx
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tecovirimat
Tradename
Company
Number
Date
Products
TPOXXSIGA TechnologiesN-208627 RX2018-07-13
1 products, RLD, RS
TPOXXSIGA TechnologiesN-214518 RX2022-05-18
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
tpoxxNew Drug Application2018-07-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
smallpox—D012899B03
Agency Specific
FDA
EMA
Expiration
Code
TECOVIRIMAT, TPOXX, SIGA TECHNOLOGIES
2025-07-13ODE-200
2023-07-13NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Tecovirimat, Tpoxx, Siga Technologies
77371682031-09-04U-2346, U-3377
92330972031-08-02DP
99078592031-08-02U-3377
105761652031-08-02DP
93394662031-03-23DS, DP
80395042027-07-23DP
81246432024-06-18DS, DP
85305092024-06-18DP
88027142024-06-18U-2346, U-3377
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AX: Other antivirals in atc
— J05AX24: Tecovirimat
HCPCS
No data
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acne vulgarisD000152EFO_0003894L708687—29
PsoriasisD011565EFO_0000676L403464218
ErythemaD004890HP_0010783L53.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acne keloidD000153L73.0——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80—1——12
Paraneoplastic syndromesD010257—1———1
Skin neoplasmsD012878EFO_0004198C44—1———1
T-cell lymphoma cutaneousD016410C84.A11———1
ExanthemaD005076R21—1———1
WartsD014860B07—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hutchinson's melanotic freckleD018327————11
Actinic keratosisD055623L57.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTECOVIRIMAT
INNtecovirimat
Description
Tecovirimat, sold under the brand name Tpoxx among others, is an antiviral medication with activity against orthopoxviruses such as smallpox and mpox. In 2018 it became the first antipoxviral drug approved in the United States.
Classification
Small molecule
Drug classantivirals: antiviral, disrupts viral maturation
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(NN1C(=O)[C@H]2[C@H]3C=C[C@H]([C@@H]4C[C@H]34)[C@H]2C1=O)c1ccc(C(F)(F)F)cc1
Identifiers
PDB—
CAS-ID869572-92-9
RxCUI—
ChEMBL IDCHEMBL1257073
ChEBI ID—
PubChem CID16124688
DrugBankDB12020
UNII IDF925RR824R (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 876 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
607 adverse events reported
View more details